Skip to main content
Logo
European Innovation Council
private sector

Faron Pharmaceuticals OY

Faron Pharmaceuticals' EIC Accelerator funded project MAGIF “Faron leading the way in macrophage guided immunotherapy” is focused on progressing the MATINS study and related business activities.

Overview

Description

Faron Pharmaceuticals' EIC Accelerator funded project MAGIF “Faron leading the way in macrophage guided immunotherapy” is focused on progressing the MATINS study and related business activities.

The ongoing phase I/II MATINS clinical trial is investigating the tolerability, safety and efficacy of Clevegen, the Company's wholly-owned novel precision cancer immunotherapy targeting Clever-1 positive tumour associated macrophages (TAM), in selected metastatic or inoperable solid tumours. 

Website
Invested amount

EUR 11 935 462

Founded

2007

Project
Press Release
Country
  • Finland
Theme
  • Health